Alpha Tau Medical Stock (NASDAQ:DRTS)
Previous Close
$2.30
52W Range
$1.75 - $3.40
50D Avg
$2.29
200D Avg
$2.53
Market Cap
$156.63M
Avg Vol (3M)
$22.95K
Beta
0.78
Div Yield
-
DRTS Company Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
DRTS Performance
Peer Comparison
Ticker | Company |
---|---|
CYT | Cyteir Therapeutics, Inc. |
TNYA | Tenaya Therapeutics, Inc. |
OCUL | Ocular Therapeutix, Inc. |
CSBR | Champions Oncology, Inc. |
ERYP | PHAXIAM Therapeutics S.A. |
INZY | Inozyme Pharma, Inc. |
HCWB | HCW Biologics Inc. |
EYEN | Eyenovia, Inc. |
MNOV | MediciNova, Inc. |
GNFT | Genfit S.A. |
MOLN | Molecular Partners AG |
ELYM | Eliem Therapeutics, Inc. |